Do analysts prefer KOO or RENX?

Kooth presently has a consensus target price of GBX 330, indicating a potential upside of 127.59%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts plainly believe Kooth is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, KOO or RENX?

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kooth £63.29M 0.83 £4.00M £7.00 20.71 Renalytix £3.30M 5.40 -£109.93M -£4.00 N/A

Is KOO or RENX more profitable?

Kooth has a net margin of 4.12% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Kooth's return on equity. Company Net Margins Return on Equity Return on Assets Kooth 4.12% 8.84% 10.12% Renalytix -506.25% 675.00% -93.54%

Do analysts prefer RENX or COG?

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Cambridge Cognition is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, FDBK or RENX?

Feedback has higher earnings, but lower revenue than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Feedback £849.62K 3.20 -£10.84M -£15.74 N/A Renalytix £3.30M 5.40 -£109.93M -£4.00 N/A

Is FDBK or RENX more profitable?

Renalytix has a net margin of -506.25% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 675.00% beat Feedback's return on equity. Company Net Margins Return on Equity Return on Assets Feedback -845.25% -135.17% -22.99% Renalytix -506.25% 675.00% -93.54%

Which has better valuation & earnings, IQAI or RENX?

IQ-AI has higher earnings, but lower revenue than Renalytix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQ-AI £538.19K 3.30 N/A N/A N/A Renalytix £3.30M 5.40 -£109.93M -£4.00 N/A

Is IQAI or RENX more profitable?

IQ-AI has a net margin of -77.52% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat IQ-AI's return on equity. Company Net Margins Return on Equity Return on Assets IQ-AI -77.52% -140.75% -22.03% Renalytix -506.25% 675.00% -93.54%

Renalytix (RENX) Competitors

GBX 4.08 +0.02 (+0.57%)

As of 11:14 AM Eastern

Compare

RENX vs. KOO, COG, INHC, FDBK, and IQAI

Should you buy Renalytix stock or one of its competitors? Renalytix's main competitors and comparable companies include Kooth (KOO), Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), and IQ-AI (IQAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Renalytix compare to Kooth?

Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Kooth presently has a consensus target price of GBX 330, indicating a potential upside of 127.59%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts plainly believe Kooth is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kooth has a beta of 1.286, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Kooth has a net margin of 4.12% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Kooth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	4.12%	8.84%	10.12%
Renalytix	-506.25%	675.00%	-93.54%

20.9% of Kooth shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 30.4% of Kooth shares are owned by company insiders. Comparatively, 5.1% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Kooth had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Kooth and 0 mentions for Renalytix. Kooth's average media sentiment score of 1.32 beat Renalytix's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Positive
Renalytix	Neutral

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	0.83	£4.00M	£7.00	20.71
Renalytix	£3.30M	5.40	-£109.93M	-£4.00	N/A

Summary

Kooth beats Renalytix on 13 of the 16 factors compared between the two stocks.

How does Renalytix compare to Cambridge Cognition?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	5.40	-£109.93M	-£4.00	N/A
Cambridge Cognition	£9.40M	1.95	-£1.58M	-£3.90	N/A

14.0% of Renalytix shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 3.2% of Cambridge Cognition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cambridge Cognition has a net margin of -17.82% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-506.25%	675.00%	-93.54%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 64.71%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Cambridge Cognition is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Renalytix has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Cambridge Cognition had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for Renalytix. Cambridge Cognition's average media sentiment score of 0.43 beat Renalytix's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company	Overall Sentiment
Renalytix	Neutral
Cambridge Cognition	Neutral

Summary

Cambridge Cognition beats Renalytix on 11 of the 16 factors compared between the two stocks.

How does Renalytix compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Induction Healthcare Group has higher revenue and earnings than Renalytix. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A
Renalytix	£3.30M	5.40	-£109.93M	-£4.00	N/A

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by insiders. Comparatively, 5.1% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Induction Healthcare Group has a net margin of -23.86% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Induction Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Induction Healthcare Group	-23.86%	-14.58%	-7.32%
Renalytix	-506.25%	675.00%	-93.54%

Induction Healthcare Group has a beta of -0.41, suggesting that its share price is 141% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

In the previous week, Induction Healthcare Group's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company	Overall Sentiment
Induction Healthcare Group	Neutral
Renalytix	Neutral

Summary

Induction Healthcare Group beats Renalytix on 6 of the 11 factors compared between the two stocks.

How does Renalytix compare to Feedback?

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

24.8% of Feedback shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 8.0% of Feedback shares are owned by insiders. Comparatively, 5.1% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Feedback has higher earnings, but lower revenue than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Feedback	£849.62K	3.20	-£10.84M	-£15.74	N/A
Renalytix	£3.30M	5.40	-£109.93M	-£4.00	N/A

Renalytix has a net margin of -506.25% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 675.00% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Feedback	-845.25%	-135.17%	-22.99%
Renalytix	-506.25%	675.00%	-93.54%

In the previous week, Feedback had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Feedback and 0 mentions for Renalytix. Feedback's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company	Overall Sentiment
Feedback	Neutral
Renalytix	Neutral

Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Summary

Feedback and Renalytix tied by winning 6 of the 12 factors compared between the two stocks.

How does Renalytix compare to IQ-AI?

IQ-AI (LON:IQAI) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

IQ-AI has higher earnings, but lower revenue than Renalytix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQ-AI	£538.19K	3.30	N/A	N/A	N/A
Renalytix	£3.30M	5.40	-£109.93M	-£4.00	N/A

IQ-AI has a net margin of -77.52% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQ-AI	-77.52%	-140.75%	-22.03%
Renalytix	-506.25%	675.00%	-93.54%

14.0% of Renalytix shares are held by institutional investors. 66.0% of IQ-AI shares are held by company insiders. Comparatively, 5.1% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IQ-AI's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company	Overall Sentiment
IQ-AI	Neutral
Renalytix	Neutral

IQ-AI has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

Summary

Renalytix beats IQ-AI on 5 of the 9 factors compared between the two stocks.

Get Renalytix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RENX vs. The Competition

Export

Metric	Renalytix	Healthcare Technology Industry	Healthcare Sector	LON Exchange
Market Cap	£17.82M	£1.62B	£7.03B	£2.88B
Dividend Yield	N/A	4.71%	2.56%	6.10%
P/E Ratio	-1.02	21.03	270.85	368.46
Price / Sales	5.40	75.92	607.83	83,426.45
Price / Cash	1.84	30.69	28.87	27.89
Price / Book	-0.38	5.62	11.09	7.08
Net Income	-£109.93M	-£26.60M	£3.45B	£5.89B
7 Day Performance	-9.38%	0.88%	0.74%	0.54%
1 Month Performance	40.62%	6.10%	2.15%	3.02%
1 Year Performance	-31.92%	-17.05%	63.00%	64.50%

Renalytix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RENX Renalytix	N/A	GBX 4.08 +0.6%	N/A	-32.3%	£17.82M	£3.30M	N/A	102	Gap Down
KOO Kooth	3.1086 of 5 stars	GBX 153 +1.7%	GBX 330 +115.7%	-6.4%	£54.59M	£63.29M	21.86	478	Positive News Gap Down
COG Cambridge Cognition	1.6226 of 5 stars	GBX 33.95 +2.9%	GBX 56 +64.9%	+36.9%	£17.81M	£9.40M	N/A	80	News Coverage
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74
FDBK Feedback	N/A	GBX 6.10 +0.8%	N/A	-52.3%	£2.65M	£849.62K	N/A	24

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:RENX) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Renalytix (RENX) Competitors